$DRTX News
Last published 2y ago
- 2y agoDRTXRA Capital Launches Structured Capital SolutionsPR NewswireRA Capital Management, LP ("RA Capital"), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare,...
- 6y agoMISTGNMKDRTXCBAY+1Milestone Pharmaceuticals Strengthens Board of Directors with Two New AppointmentsPR NewswireMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
- 13y agoDRTXDurata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSIBusiness WireCHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results for its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacte ...
- 13y agoDRTXDurata Therapeutics to Host Conference Call and Webcast on December 11, 2012 at 9:00AM ET to Present Preliminary Top-line Results from its DISCOVER 1 StudyBusiness WireCHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that it will host a conference call and webcast at 9:00am Eastern Time on Tuesday, December 11, 2012 to present preliminary top-line results from its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the tr ...
- 14y agoDRTXDurata Therapeutics Relocating Corporate Headquarters to ChicagoBusiness WireMORRISTOWN, N.J & CHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) is working with the Illinois Department of Commerce and Economic Opportunity to relocate Durata's corporate headquarters to Chicago from Morristown, N.J. The State of Illinois' news release below provides additional details and background.
- 14y agoDRTXDurata Therapeutics Reports Third Quarter 2012 Financial and Corporate ResultsBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial and corporate results for the quarter ended September 30, 2012.
- 14y agoDRTXDurata Therapeutics to Present at Credit Suisse 2012 Healthcare ConferenceBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that Durata Chief Executive Officer Paul R. Edick will present an overview of the company at the Credit Suisse Healthcare Conference. The Durata presentation will take place at The Arizona Biltmore, Phoenix, Arizona on Thursday, November 15, 2012 at 3:00 p.m. MST.
- 14y agoDRTXFDA Designates Durata Therapeutics’ Dalbavancin a Qualified Infectious Disease Product (QIDP)Business WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that the U.S. Food and Drug Administration (FDA) has designated dalbavancin as a Qualified Infectious Disease Product (QIDP). The QIDP designation provides Durata priority review by the FDA, eligibility for fast-track status, and extension of statutory exclusivity periods for an additional five years upon FDA app ...
- 14y agoDRTXDurata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 2 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in ABSSSI PatientsBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that it has completed its target enrollment for DISCOVER 2 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”), the second global, Phase 3 clinical trial of Durata’s lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin struc ...
- 14y agoDRTXDurata Therapeutics Presents Results from Skin Lesion Measurement Study at IDWeek 2012Business WireSAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced data from a multicenter, observational study related to the clinical development program of its lead product candidate, dalbavancin. The results demonstrate the reliability of the measurement tools deployed by Durata Therapeutics in its two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial sk ...
- 14y agoDRTXDurata Therapeutics Announces Preclinical Data Supporting Clinical Development of Dalbavancin for the Treatment of PneumoniaBusiness WireSAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced in vitro study data that could help support a clinical development program to investigate its lead product candidate, dalbavancin, for the treatment of pneumonia. In this study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalba ...
- 14y agoDRTXDurata Therapeutics Names Allison Wey as Vice President, Investor Relations and Public AffairsBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced the appointment of Allison Wey as the company’s vice president of Investor Relations and Public Affairs. Ms. Wey, who joined the company’s Chicago office today, brings to Durata more than 25 years of experience in investor relations, financial communications and corporate communications.
- 14y agoDRTXDurata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012Business WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from two clinical trials of its lead product candidate, dalbavancin, will be presented in two posters during the IDWeek conference in San Diego from October 17-21, 2012.
- 14y agoDRTXDurata Therapeutics to Present at 11th Annual BIO Investor ForumBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that Durata Chief Executive Officer Paul R. Edick has been invited to deliver an overview of the company at the 11th Annual BIO Investor Forum. The Durata presentation will take place on Wednesday, October 10, 2012 at 1:30 p.m. PT in the Presidio Room of the Palace Hotel in San Francisco.
- 14y agoDRTXDurata Therapeutics Announces Completion of QT Study of DalbavancinBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced results from its QT study of the company’s lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The QT study data, presented at the 52nd Interscience Conferen ...
- 14y agoDRTXData Showing Potential Economic Benefits of Treating ABSSSI in Outpatient Settings Presented at ICAAC 2012Business WireSAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ:DRTX) today announced cost-analysis data from a study investigating outpatient-based therapy for acute bacterial skin and soft tissue infections (abSSTI, a term synonymous with the more commonly used acute bacterial skin and skin structure infections, or ABSSSI). The data, presented at the 52nd Interscience Conference on Antimicrobial Age ...
- 14y agoDRTXNew Data Demonstrating Potency of Durata Therapeutics’ Dalbavancin Against Bacterial Pathogens Presented at ICAAC 2012Business WireSAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The data, presented at the 52nd Interscience Conference on A ...
- 14y agoDRTXDurata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 1 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in abSSSI PatientsBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that it has completed its target enrollment for DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”), one of two ongoing, global, Phase 3 clinical trials of Durata’s lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and ...
- 14y agoDRTXDurata Therapeutics, Inc. Reports Second Quarter 2012 Financial and Corporate ResultsBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, today announced financial and corporate results for the quarter ended June 30, 2012.
- 14y agoDRTXDurata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012Business WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will be hel ...
- 14y agoDRTXDurata Therapeutics to Present at BioCentury NewsMakers ConferenceBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that Paul Edick, Chief Executive Officer, will present an overview of the company at the 2012 BioCentury NewsMakers in the Biotech Industry conference.
- 14y agoDRTXDurata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s BoardBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that, as contemplated by the prospectus related to the company’s initial public offering, the company’s board of directors appointed a new independent director to the board to replace one of the company’s existing directors who is transitioning off the board. The board has appointed Lisa Giles, CEO & President of ...
- 14y agoDRTXDurata Therapeutics Closes Initial Public OfferingBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public o ...
- 14y agoDRTXDurata Therapeutics Prices Initial Public OfferingBusiness WireMORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol “DRTX."